3 completed, 1 recruiting. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Complicated Urinary Tract Infection (cUTI): new trials by email Literature Review of Complicated Urinary Tract Infection (cUTI) trials Research Report on Complicated Urinary Tract Infection (cUTI)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam) - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 80 | 2025-04-12 | 2025-07-30 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants Cefiderocol, Standard of Care - Gram-negative Bacterial Infections, Bloodstream Infections (BSI) | Phase 2 | Completed | Shionogi | 53 | 2020-08-21 | 2026-02-27 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants Cefiderocol, Standard of Care - Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP) | Phase 2 | Completed | Shionogi | 91 | 2020-02-19 | 2025-05-25 |
| Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Cefiderocol, Best Available Therapy - Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI) | Phase 3 | Completed | Shionogi | 152 | 2016-09-07 | 2021-01-12 |
Sepsis (3) · Gram-Negative Bacterial Infections (2) · Healthcare-Associated Pneumonia (2) · Pneumonia, Ventilator-Associated (2)
Infections (4) · Inflammation (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Systemic Inflammatory Response Syndrome (3) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Cross Infection (2) · Disease Attributes (2) · Iatrogenic Disease (2) · Lung Diseases (2) · Pneumonia (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2)
Cefiderocol (3) · Standard of Care (2) · Colistin (1) · Meropenem (1)
Shionogi (3) · Qilu Pharmaceutical Co., Ltd. (1)
Spain (3) · Georgia (2) · Greece (2) · Thailand (2) · Ukraine (2) · United States (2) · Australia (1) · Belgium (1) · Brazil (1) · China (1) · Croatia (1) · Estonia (1) · France (1) · Germany (1) · Guatemala (1)
PMID 39230271, PMID 31819544, PMID 33058795, PMID 33393598, PMID 34792787, PMID 35076335
2019 (2), 2015 (1)